Related Experiment Video
Updated: Jul 20, 2026
Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals
Published on: January 5, 2016
Convalescent Plasma in COVID-19
Ranjit S Banwait1, Joshua K Salabei1, Troy J Fishman1
1University of Central Florida/ HCA Healthcare North Florida Regional Medical Center.
Abstract:
Description The recent pandemic of SARS-CoV-2, which causes novel coronavirus disease 2019 (Covid-19), has had devastating impact on a global and national scale. In order to overcome this outbreak it is imperative we find treatments that are safe and effective. To date, no definitive treatment is available that can curtail the spread of this viral syndrome. Convalescent plasma (CP) is one such option that has repeatedly served as an important tool in treatment of various bacterial and viral infections, especially in the setting of no specific antimicrobial or vaccination against an infectious disease. Herein, we review the history of CP, prior usage of CP in various infections and pandemics to date, mechanism of action of the same and conclude with a brief overview of the experience gained so far with use of CP in COVID-19.
Insights
Convalescent plasma (CP) is a potential treatment for COVID-19, offering an option when no definitive therapies exist. This review examines CP
Area of Science:
- Infectious Diseases
- Immunology
- Virology
Background:
- The COVID-19 pandemic caused by SARS-CoV-2 has created a global health crisis.
- Effective treatments are urgently needed to combat the spread of SARS-CoV-2.
- No definitive antiviral treatment currently exists for COVID-19.
Purpose of the Study:
- To review the historical use of convalescent plasma (CP) in treating infections.
- To explore the mechanism of action of CP.
- To summarize current experiences with CP for COVID-19 treatment.
Main Methods:
- Literature review of historical CP usage.
- Analysis of CP's therapeutic mechanisms.
- Compilation of data on CP application in COVID-19.
Main Results:
- Convalescent plasma has a history of use in various infectious diseases.
- CP contains antibodies that may neutralize pathogens.
- Early experiences with CP in COVID-19 are being documented.
Conclusions:
- Convalescent plasma is a viable therapeutic option for COVID-19.
- Further research is needed to fully establish CP efficacy and safety.
- CP represents a promising approach in the absence of specific treatments.
